Drugs / TAF
last change Jan 2021 re-read 2 minutes ago

TAF

Developed for
chronic hepatitis B virus infection
Investigated by
F-star Therapeutics, Inc. · Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03434353 Feb 2018 → Jan 2020 chronic hepatitis B virus infection Gilead Sciences Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT03434353
Route Oral “Administered orally once daily with food” NCT03434353